Furthermore, it is conceivable that the dysregulation of immunological mediators implicated in COVID-19, including IL-6, sIL-6R, and sgp130, may contribute to varied prognoses and responses to pharmacological interventions such as tocilizumab and steroids. Here, IL6 is linked to COVID-19.